Serum stabilities of short tryptophan-and arginine-rich antimicrobial peptide analogs LT Nguyen, JK Chau, NA Perry, L de Boer, SAJ Zaat, HJ Vogel PloS one 5 (9), e12684, 2010 | 399 | 2010 |
In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age NAP Lieberman, V Peddu, H Xie, L Shrestha, ML Huang, MC Mears, ... PLoS biology 18 (9), e3000849, 2020 | 260 | 2020 |
Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy NAP Lieberman, K DeGolier, HM Kovar, A Davis, V Hoglund, J Stevens, ... Neuro-oncology 21 (1), 83-94, 2019 | 148 | 2019 |
SARS-CoV-2 ORF6 disrupts bidirectional nucleocytoplasmic transport through interactions with Rae1 and Nup98 A Addetia, NAP Lieberman, Q Phung, TY Hsiang, H Xie, P Roychoudhury, ... MBio 12 (2), 10.1128/mbio. 00065-21, 2021 | 105* | 2021 |
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain VK Outlaw, FT Bovier, MC Mears, MN Cajimat, Y Zhu, MJ Lin, A Addetia, ... MBio 11 (5), 10.1128/mbio. 01935-20, 2020 | 71 | 2020 |
Genetically engineered macrophages: a potential platform for cancer immunotherapy KW Moyes, NAP Lieberman, SA Kreuser, H Chinn, C Winter, G Deutsch, ... Human gene therapy 28 (2), 200-215, 2017 | 70 | 2017 |
Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State NF Müller, C Wagner, CD Frazar, P Roychoudhury, J Lee, LH Moncla, ... Science Translational Medicine 13 (595), eabf0202, 2021 | 66 | 2021 |
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models NA Vitanza, MC Biery, C Myers, E Ferguson, Y Zheng, EJ Girard, ... Neuro-oncology 23 (3), 376-386, 2021 | 61 | 2021 |
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses KJ Brempelis, CM Cowan, SA Kreuser, KP Labadie, BM Prieskorn, ... Journal for immunotherapy of cancer 8 (2), 2020 | 59 | 2020 |
Obscurins: Goliaths and Davids take over non-muscle tissues MA Ackermann, M Shriver, NA Perry, LYR Hu, ... PloS one 9 (2), e88162, 2014 | 53 | 2014 |
Treponema pallidum genome sequencing from six continents reveals variability in vaccine candidate genes and dominance of Nichols clade strains in Madagascar NAP Lieberman, MJ Lin, H Xie, L Shrestha, T Nguyen, ML Huang, ... PLoS neglected tropical diseases 15 (12), e0010063, 2021 | 52 | 2021 |
Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection M Ferren, V Favède, D Decimo, M Iampietro, NAP Lieberman, JL Weickert, ... Nature Communications 12 (1), 5809, 2021 | 49 | 2021 |
Obscurins: unassuming giants enter the spotlight NA Perry, MA Ackermann, M Shriver, LYR Hu, ... IUBMB life 65 (6), 479-486, 2013 | 49 | 2013 |
Loss of giant obscurins promotes breast epithelial cell survival through apoptotic resistance NA Perry, M Shriver, MG Mameza, B Grabias, E Balzer, ... The FASEB Journal 26 (7), 2764, 2012 | 45 | 2012 |
Genetic engineering of Treponema pallidum subsp. pallidum, the Syphilis Spirochete E Romeis, L Tantalo, N Lieberman, Q Phung, A Greninger, L Giacani PLoS Pathogens 17 (7), e1009612, 2021 | 41 | 2021 |
Evaluation and clinical validation of monkeypox (mpox) virus real-time PCR assays MG Mills, KB Juergens, JP Gov, CJ McCormick, R Sampoleo, A Kachikis, ... Journal of Clinical Virology 159, 105373, 2023 | 34 | 2023 |
Novel obscurins mediate cardiomyocyte adhesion and size via the PI3K/AKT/mTOR signaling pathway MA Ackermann, B King, NAP Lieberman, PJ Bobbili, M Rudloff, ... Journal of molecular and cellular cardiology 111, 27-39, 2017 | 33 | 2017 |
Immunotherapy for brain tumors: understanding early successes and limitations NAP Lieberman, NA Vitanza, CA Crane Expert review of neurotherapeutics 18 (3), 251-259, 2018 | 32 | 2018 |
Loss of the obscurin-RhoGEF downregulates RhoA signaling and increases microtentacle formation and attachment of breast epithelial cells NA Perry, MI Vitolo, SS Martin, A Kontrogianni-Konstantopoulos Oncotarget 5 (18), 8558, 2014 | 31 | 2014 |
An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells NAP Lieberman, K DeGolier, K Haberthur, H Chinn, KW Moyes, ... Frontiers in Immunology 9, 150, 2018 | 30 | 2018 |